Question special
Lead Moderator

Many of the patients we'd expect to have elevated hs-CRP were exluded from the CANTOS trial. The exclusion of patients on other anti-inflammatory drugs likely excluded most patients with active rheumatologic disease. Further, patients with infections (chronic and acute) and with history of malignancy were excluded. Of the patients who were not excluded, why do they have elevated hs-CRP? In terms of CVD risk and impact of canakinumab, do you think the underlying cause matters?